EnBio Holdings (TSE:6092) Current Deferred Revenue: 円0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:6092 EnBio Holdings Inc TSE:6092
58 GF Score
Price 円812.00
GF Value 円809.91
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is EnBio Holdings Current Deferred Revenue?

EnBio Holdings TSE:6092 58 Current Deferred Revenue is 円0 Mil as of Mar. 2026. GuruFocus rates TSE:6092 with a GF Score™ of 58/100 and a GF Value™ of 円809.91 (Fairly Valued). The stock has 7 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

EnBio Holdings's current deferred revenue for the quarter that ended in Mar. 2026 was 円0 Mil.

EnBio Holdings Current Deferred Revenue Related Terms

EnBio Holdings Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for EnBio Holdings's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EnBio Holdings Current Deferred Revenue Chart

EnBio Holdings Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

EnBio Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:6092
58GF Score
EnBio Holdings Inc TSE:6092
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of 円0 Mil mean?
EnBio Holdings (TSE:6092) has a Current Deferred Revenue of 円0 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on EnBio Holdings and its competitors.
Is EnBio Holdings' Current Deferred Revenue too high?
EnBio Holdings' current Current Deferred Revenue is 円0 Mil. Overall, EnBio Holdings has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does EnBio Holdings' Current Deferred Revenue compare to CTAS and CPRT?
EnBio Holdings' Current Deferred Revenue of 円0 Mil can be compared against companies in the Business Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Business Services company?
A good Current Deferred Revenue depends on the Business Services industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on EnBio Holdings and its competitors. EnBio Holdings's current Current Deferred Revenue is 円0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EnBio Holdings stock overvalued right now?
Based on GuruFocus' analysis, EnBio Holdings (TSE:6092) is currently considered Fairly Valued. The stock's GF Value™ is 円809.91, compared to a current price of 円812.00 — trading 0.3% above its estimated fair value. The current Current Deferred Revenue is 円0 Mil. EnBio Holdings' overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For EnBio Holdings (TSE:6092), the current Current Deferred Revenue is 円0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is EnBio Holdings (TSE:6092) Overvalued in 2026?

Based on GuruFocus' analysis, EnBio Holdings stock appears to be overvalued. The current stock price of 円812.00 is trading 0.3% above its estimated GF Value™ of 円809.91. GuruFocus considers EnBio Holdings to be Fairly Valued.

Key valuation signals for TSE:6092:

  • Current Deferred Revenue: 円0 Mil
  • GF Value™: 円809.91 vs. price of 円812.00 (0.3% above fair value)
  • GF Score™: 58/100 with 7 warning signs

No single metric tells the full story. See the TSE:6092 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

EnBio Holdings Business Description

Address Tokyo Kandata cho 2-11 O-machi Takaku Building 3F, Chiyoda-ku, Tokyo, JPN
EnBio Holdings Inc is a Japanese company engaged in environmental solution business, tools and chemicals business, and brownfield revitalization business. The environmental business involves investigation, remediation and risk management consulting of contaminated soil and groundwater; Tools and chemicals business involves sales of chemicals used for environmental work such as site investigation and remediation; and brownfield revitalization business which involves purchasing and regeneration of brownfields. The objective of the company is solving soil and groundwater contamination issues.
58GF Score

Get the complete analysis for TSE:6092

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円812.00
Price
円809.91
GF Value